GSK Begins Study With Bronchodilator

GlaxoSmithKline (GSK) has started a Phase I trial of inhaled bronchodilator GSK1160724 for the treatment of chronic obstructive pulmonary disease (COPD).

The compound was discovered by Theravance and is being developed by GSK under the parties' strategic alliance agreement.

GSK1160724 is a long-acting muscarinic antagonist (LAMA) and is part of a drug discovery program dedicated to finding medicines for respiratory diseases such as COPD and asthma, according to Theravance.

The LAMA program is one of three respiratory programs being developed by the companies.